TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19581810

Group type: EXPERIMENTAL
Intervention: Optimized treatment with oral lansoprazole
Number of subjects: 67

Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Basal acid output >5 mmol/h
Number of subjects: 67

Group type: COMPARATOR
Intervention: Poor compliance
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Protocol driven charges
Number of subjects: 67
Study: 19583857

Group type: EXPERIMENTAL
Intervention: Fast-track intervention for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care during 8-week waiting period
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fast-track trial methodology
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline/outcome measures
Number of subjects: 20
Study: 19584400

Group type: EXPERIMENTAL
Intervention: ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) administered every 21 days
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ABVE-PC followed by 21 Gy radiation for rapid early responders
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ABVE-PC followed by 21 Gy radiation for slow early responders after 2 additional cycles
Number of subjects: 216
Study: 19586800

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day)
Number of subjects: 37
Study: 19587341

Group type: EXPERIMENTAL
Intervention: Intraarticular delivery of a TNF-alpha antagonist via an AAV type 2 delivery system
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Concurrent anti-TNF-alpha therapy and other immunosuppressive therapy
Number of subjects: 1
Study: 19587363

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 27
Study: 19587528

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02A vaccine (3 doses according to a 0-1-2 months schedule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02A vaccine
Number of subjects: 0
Study: 19593212

Group type: EXPERIMENTAL
Intervention: SNPs in IL15, NPY2R, and NPY5R in blacks
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: SNPs in NPY1R, NPY2R, NPY5R, CPE, IL15, and SFRP2
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: SNPs in NPY2R, NPY5R, and SFRP2 in whites
Number of subjects: 885
Study: 19594547

Group type: EXPERIMENTAL
Intervention: Oral fludarabine in combination with rituximab (375 mg/m² rituximab on day 1, 40 mg/m² oral fludarabine once daily on days 1-5 every 28 days for up to six cycles)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral fludarabine in combination with rituximab
Number of subjects: 41
Study: 19594946

Group type: EXPERIMENTAL
Intervention: 10-6 M Dexamethasone (Dex)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Steroid-sensitive (SS) patients
Number of subjects: 35
Study: 19597050

Group type: EXPERIMENTAL
Intervention: Systematic clinical testing including cardiac magnetic resonance imaging, signal-averaged ECG, exercise testing, drug challenge, and selective electrophysiological testing.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Targeted genetic testing.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Family screening of 64 family members of these patients.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Systematic clinical testing (overall approach).
Number of subjects: 63
Study: 19601706

Group type: EXPERIMENTAL
Intervention: Intra-articular Hylan G-F 20 injections
Number of subjects: 32
Study: 19602710

Group type: EXPERIMENTAL
Intervention: ITD integration site in the beta1-sheet of the tyrosine kinase domain-1 (TKD1)
Number of subjects: 241
Study: 19604722

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin with docetaxel) followed by accelerated concomitant boost radiotherapy (44 Gy in 22 fractions) and definitive surgery
Number of subjects: 46
Study: 19605490

Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara/fowlpox virus-based HIV-1 vaccines
Number of subjects: 20
Study: 19605831

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Optical colonoscopy
Number of subjects: 328
Study: 19606043

Group type: EXPERIMENTAL
Intervention: Vigileo cardiac output monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LiDCOplus cardiac output monitor
Number of subjects: 0
Study: 19608028

Group type: EXPERIMENTAL
Intervention: Continuous-flow rotary left ventricular assist device (LVAD)
Number of subjects: 281
Study: 19608137

Group type: EXPERIMENTAL
Intervention: Intracoronary NIRS system for detection of lipid core-containing plaques (LCP)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intracoronary NIRS system
Number of subjects: 89
Study: 19608533

Group type: EXPERIMENTAL
Intervention: Electrical stimulation using a prototype epiretinal prosthesis with a 4 x 4 array of 16 stimulating electrodes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation using the prosthetic device.
Number of subjects: 0
Study: 19608747

Group type: EXPERIMENTAL
Intervention: Myeloablative (MA) regimen with CD34(+) counts greater than 3.8 x 10(6)/kg
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: All preparative regimens with CD34(+) cell doses exceeding 4.5 x 10(6)/kg
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Myeloablative (MA) regimen
Number of subjects: 932

Group type: COMPARATOR
Intervention: Reduced-intensity (RI) and nonmyeloablative (NMA) regimens
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Reduced-intensity (RI) regimen
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative (NMA) regimen
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Higher CD34(+) cell doses
Number of subjects: 932
Study: 19615094

Group type: EXPERIMENTAL
Intervention: Behavioral intervention study (PROMISE EBF)
Number of subjects: 877
Study: 19615672

Group type: EXPERIMENTAL
Intervention: Smoking pregnant women (SPW)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Lifetime nonsmoking pregnant women (NSPW)
Number of subjects: 59
Study: 19615940

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally once daily on schedule 4-2 (4 weeks on treatment, 2 weeks off)
Number of subjects: 4371
Study: 19616281

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily until disease progression
Number of subjects: 29
Study: 19617402

Group type: EXPERIMENTAL
Intervention: Patients whose family members returned surveys about end-of-life care
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Patients whose family members did not return surveys about end-of-life care
Number of subjects: 2016
Study: 19618202

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 37
Study: 19619781

Group type: EXPERIMENTAL
Intervention: Hemosiderin foci present
Number of subjects: 48

Group type: COMPARATOR
Intervention: No hemosiderin foci
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Presence of hemosiderin foci
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Small stroke
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Periventricular leukomalacia
Number of subjects: 48
Study: 19620489

Group type: EXPERIMENTAL
Intervention: 32 or 36 Gy in 4-Gy fractions, given twice daily (36 Gy cohort with pure photons)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ILV receiving 20 Gy or higher (ILV, 20 Gy) of 3% or higher
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ILV 10 Gy of 10% or higher
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ILV 5 Gy of 20% or higher
Number of subjects: 198
Study: 19620516

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (1 g twice daily) for 24 weeks
Number of subjects: 32
Study: 19621454

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 19624460

Group type: EXPERIMENTAL
Intervention: Dalteparin injected subcutaneously (s.c.) twice daily at a median dose of 90 (73-106) units kg(-1) per 12 h
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dalteparin injected subcutaneously (s.c.) twice daily
Number of subjects: 32
Study: 19625715

Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 37673

Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 37673

Group type: EXPERIMENTAL
Intervention: Vi vaccine (children aged 2-5 years)
Number of subjects: 37673

Group type: EXPERIMENTAL
Intervention: Vi vaccine (unvaccinated neighbors)
Number of subjects: 37673

Group type: EXPERIMENTAL
Intervention: Vi vaccine (overall residents in clusters)
Number of subjects: 37673
Study: 19628125

Group type: EXPERIMENTAL
Intervention: Spontaneous myocardial infarction (MI)
Number of subjects: 7773

Group type: EXPERIMENTAL
Intervention: Periprocedural myocardial infarction (MI)
Number of subjects: 7773

Group type: COMPARATOR
Intervention: No myocardial infarction (MI)
Number of subjects: 7773
Study: 19628656

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) for 18 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 14
Study: 19629020

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmaceutical antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotic medications
Number of subjects: 0
Study: 19629306

Group type: EXPERIMENTAL
Intervention: ACS with ST-segment elevation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: ACS (both groups)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (blood donors without known coronary disease)
Number of subjects: 126
Study: 19630971

Group type: EXPERIMENTAL
Intervention: Erythropoietin (epoietin-beta) at high doses (1,500 U/kg/day for three days) combined with quinine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Erythropoietin (epoietin-beta) at high doses combined with quinine
Number of subjects: 35
Study: 19631001

Group type: EXPERIMENTAL
Intervention: Emergency department physician activation of the catheterization lab and immediate transfer to catheterization lab by in-house transfer team.
Number of subjects: 132
Study: 19632952

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 36
Study: 19632975

Group type: EXPERIMENTAL
Intervention: American Indian or Alaskan Native (AI/AN)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: African American (AA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Caucasian
Number of subjects: 45
Study: 19633200

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy, bone marrow transplantation, or gene therapy in ADA-deficient neonatal mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy with ADA-transduced hematopoietic stem cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated ADA-severe combined immunodeficiency patients
Number of subjects: 0
Study: 19635928

Group type: EXPERIMENTAL
Intervention: Inhalation of acid sphingomyelinase inhibitors (amitriptyline, trimipramine, desipramine, chlorprothixene, fluoxetine, amlodipine, sertraline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet with Peptamen
Number of subjects: 0
Study: 19635999

Group type: EXPERIMENTAL
Intervention: NOTCH1 and FBXW7 mutations (MUT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: NOTCH1 mutations (MUT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: FBXW7 mutations (MUT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wild type (WT) for both markers
Number of subjects: 88
Study: 19636002

Group type: EXPERIMENTAL
Intervention: Bevacizumab, capecitabine, and radiation (50.4 Gy per 28 fractions, capecitabine 825 mg/m² orally twice daily on days of radiation, bevacizumab 5 mg/kg on days 1, 15, and 29, followed by maintenance gemcitabine 1 g/m² weekly for 3 weeks and bevacizumab 5 mg/kg every 2 weeks)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Bevacizumab, capecitabine, and radiation
Number of subjects: 82
Study: 19636006

Group type: EXPERIMENTAL
Intervention: Talampanel with standard radiation (RT) and temozolomide (TMZ)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Talampanel with RT + TMZ
Number of subjects: 72
Study: 19636010

Group type: EXPERIMENTAL
Intervention: Dacetuzumab (2 mg/kg weekly for 4 weeks, with dose escalation up to 8 mg/kg)
Number of subjects: 50
Study: 19638109

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation/aspirator device
Number of subjects: 16
Study: 19638218

Group type: EXPERIMENTAL
Intervention: Familial keloids
Number of subjects: 5
Study: 19638905

Group type: EXPERIMENTAL
Intervention: Subcutaneous mastectomy with nipple-areola skin conservation
Number of subjects: 96
Study: 19640291

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 19640956

Group type: EXPERIMENTAL
Intervention: Vitamin D status measured by 25-hydroxyvitamin D [25(OH)D] levels
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bone mineral content and bone mineral density
Number of subjects: 58
Study: 19641161

Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging of tissue oxyhemoglobin and deoxyhemoglobin
Number of subjects: 66
Study: 19641201

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 4776

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 4776

Group type: COMPARATOR
Intervention: Composite end point of 30-day major adverse outcomes
Number of subjects: 4776

Group type: COMPARATOR
Intervention: Extreme values of body-mass index
Number of subjects: 4776

Group type: COMPARATOR
Intervention: Age, sex, race, ethnic group, and other coexisting conditions
Number of subjects: 4776
Study: 19641325

Group type: EXPERIMENTAL
Intervention: Rosiglitazone, 4 mg daily for 6 months
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 3
Study: 19643246

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Retained feeding tube
Number of subjects: 54

Group type: COMPARATOR
Intervention: Complications
Number of subjects: 54
Study: 19643318

Group type: EXPERIMENTAL
Intervention: MRI at 1.5-T with specific absorption rate limited to 2 W/kg; ICDs reprogrammed pre-MRI
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MRI at 1.5-T
Number of subjects: 18
Study: 19643971

Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 80
Study: 19643983

Group type: EXPERIMENTAL
Intervention: Subcutaneous alemtuzumab
Number of subjects: 99
Study: 19646269

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with 9-1-1 call takers to identify themes and belief categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative survey designed based on qualitative results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final version of the quantitative survey administered to all registered call takers
Number of subjects: 0
Study: 19648219

Group type: EXPERIMENTAL
Intervention: Bupropion and group therapy for 2 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Watching videotape showing smoking scenes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ratings of urge to smoke while watching smoking scenes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control movie
Number of subjects: 22
Study: 19648970

Group type: EXPERIMENTAL
Intervention: Topotecan at 4.5 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topotecan at 6.0 mg/m(2)/d combined with CY 1.5 g/m(2)/d and carboplatin 200 mg/m(2)/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Topotecan (various doses)
Number of subjects: 16
Study: 19649755

Group type: EXPERIMENTAL
Intervention: Nonfunctional adrenal incidentaloma (NFA) patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Age, total cholesterol, presence of adrenal incidentaloma
Number of subjects: 35
Study: 19650932

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 19651065

Group type: EXPERIMENTAL
Intervention: Topical recombinant human thrombin (rThrombin) applied during surgical procedure (day 1)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Topical recombinant human thrombin (rThrombin)
Number of subjects: 209
Study: 19652055

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice daily until tumor progression or unacceptable toxicity
Number of subjects: 54
Study: 19652067

Group type: EXPERIMENTAL
Intervention: Pralatrexate at a dose of 30 mg/m(2) weekly for 6 weeks every 7 weeks (MTD established in phase I/II study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pralatrexate at a dose of 135 mg/m(2) every other week
Number of subjects: 48
Study: 19652199

Group type: EXPERIMENTAL
Intervention: Gamma-retroviral vectors (RVs) gene therapy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study: 19652201

Group type: EXPERIMENTAL
Intervention: 5-azacytidine and entinostat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (de novo AML patients and normal CD34(+) bone marrow cells)
Number of subjects: 0
Study: 19652630

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Type 6/11/16/18)
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study: 19654407

Group type: EXPERIMENTAL
Intervention: MICA-mismatched patients
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: HLA 10/10 match with MICA mismatch
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: HLA any mismatch with MICA mismatch
Number of subjects: 236

Group type: COMPARATOR
Intervention: MICA-matched patients
Number of subjects: 236

Group type: COMPARATOR
Intervention: HLA 10/10 match without MICA mismatch
Number of subjects: 236

Group type: COMPARATOR
Intervention: HLA any mismatch without MICA mismatch
Number of subjects: 236
Study: 19656016

Group type: EXPERIMENTAL
Intervention: New teriparatide delivery device
Number of subjects: 199
Study: 19657114

Group type: EXPERIMENTAL
Intervention: Interfant-99 protocol
Number of subjects: 30
Study: 19659963

Group type: EXPERIMENTAL
Intervention: Alitretinoin
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patient Benefit Index for chronic hand eczema (PBI-HE)
Number of subjects: 249
Study: 19660694

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and spectroscopic (MRS) correlates of functional capacity
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: PCr measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Calf muscle perfusion measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Overall findings from MRI and spectroscopy
Number of subjects: 85
Study: 19661245

Group type: EXPERIMENTAL
Intervention: Proximal GER
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Distal GER
Number of subjects: 304

Group type: COMPARATOR
Intervention: No GER
Number of subjects: 304
Study: 19663124

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler, 400 microg/d for 8 weeks
Number of subjects: 11
Study: 19663708

Group type: EXPERIMENTAL
Intervention: HBV vaccine booster
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Subsequent HBV vaccination 4-5 years later
Number of subjects: 204
Study: 19664276

Group type: EXPERIMENTAL
Intervention: AC-1202
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 19664754

Group type: EXPERIMENTAL
Intervention: High-dose intravenous daclizumab (8 mg/kg at baseline, 4 mg/kg at week 2, 2 mg/kg every 4 weeks for 52 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose intravenous daclizumab
Number of subjects: 6
Study: 19666119

Group type: EXPERIMENTAL
Intervention: IRL-1620 (1.6 microg/kg, i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRL-1620 (5.0 microg/kg, i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRL-1620 (15.0 microg/kg, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ET(A) antagonist BMS187824 (5 mg/kg, i.v.) followed by IRL-1620 (5 microg/kg, i.v.)
Number of subjects: 0
Study: 19667400

Group type: EXPERIMENTAL
Intervention: Post-alloHSCT serum antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human antibody-binding fragment (Fab) library
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoglobulin G1 (IgG1) converted Fab
Number of subjects: 0
Study: 19669729

Group type: EXPERIMENTAL
Intervention: Serum IL-6 levels
Number of subjects: 33

Group type: COMPARATOR
Intervention: Serum TNF-alpha or hsCRP levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Plasma DAG levels
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Circulating levels of ceramides and TNF-alpha
Number of subjects: 33
Study: 19670189

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with de novo CNI minimization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard CNI-based immunosuppressive regimens (MMF group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tacrolimus therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 6-month estimated glomerular filtration rate (eGFR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acute rejection
Number of subjects: 100
Study: 19670912

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infusion every 8 hours
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg (1- or 4-hour infusion every 8 hours)
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: Doripenem for patients with seizure-predisposing conditions
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam for patients with seizure-predisposing conditions
Number of subjects: 1332

Group type: COMPARATOR
Intervention: Imipenem for patients with seizure-predisposing conditions
Number of subjects: 1332